Study of Trospium Chloride Inhalation Powder (TrIP) in Patients With Chronic Obstructive Pulmonary Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

To assess the effect of a single dose of TrIP on pulmonary function in patients with COPD

Key facts

Study ID

NCT00465959

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

24

Starts

2007-04-01

Expected to finish

2007-06-01

Last updated by the study team

2013-12-27

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female COPD patients between the ages of 40 and 80 years
• Smoking history of at least 10 pack years
• Not currently using (or able to wash out of) any long acting bronchodilators

You may not qualify if…

• Candidate on a waiting list for surgery while on study
• Using long-term oxygen therapy
• Hospitalization for COPD exacerbation

Where it is running

• United States Investigational Site — Spartanburg, South Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.